Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma

References

• Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585–98.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333–8.
   PubMed Web of Science ®Google Scholar
• Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13:167–80.
   PubMed Web of Science ®Google Scholar
• Jernberg-Wiklund H, Nilsson K. Multiple myeloma cell lines. In: Waters J, Palsson B, editors. Cancer cell lines part 3: leukemias and lymphomas. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2000. p 81–155.
   Google Scholar
• Vanderkerken K, Asosingh K, Willems A, De Raeve H, Couck P, Gorus F, The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol Med. 2005;113:191–205.
   PubMedGoogle Scholar
• Li Z, Zhu YX, Plowright EE, Bergsagel PL, Chesi M, Patterson B, The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood. 2001;97:2413–19.
   PubMed Web of Science ®Google Scholar
• Sehat B, Tofigh A, Lin Y, Trocme E, Liljedahl U, Lagergren J, SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal. 2010;3:ra10.
   PubMed Web of Science ®Google Scholar
• De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 2010;115:2430–40.
   PubMed Web of Science ®Google Scholar
• Kalushkova A, Fryknas M, Lemaire M, Fristedt C, Agarwal P, Eriksson M, Polycomb target genes are silenced in multiple myeloma. PLoS One. 2010;5:e11483.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20:571–96.
   PubMed Web of Science ®Google Scholar
• Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003;102:4504–11.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134:573–89.
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, The molecular classification of multiple myeloma. Blood. 2006;108:2020–8.
   PubMed Web of Science ®Google Scholar
• Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543–53.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607–18.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117:2009–11.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008;22:2280–4.
   PubMed Web of Science ®Google Scholar
• Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia. 1994;8:758–67.
   PubMed Web of Science ®Google Scholar
• Kulkarni MS, Daggett JL, Bender TP, Kuehl WM, Bergsagel PL, Williams ME. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia. 2002;16:127–34.
   PubMed Web of Science ®Google Scholar
• Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood. 2000;96:2856–61.
   PubMed Web of Science ®Google Scholar
• Lode L, Eveillard M, Trichet V, Soussi T, Wuilleme S, Richebourg S, Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95:1973–6.
   PubMed Web of Science ®Google Scholar
• Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA. 2000;97:228–33.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011;25:1026–35.
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, IRF4 addiction in multiple myeloma. Nature. 2008;454:226–31.
   PubMed Web of Science ®Google Scholar
• Potter M. Perspectives on the origins of multiple myeloma and plasmacytomas in mice. Hematol Oncol Clin North Am. 1992;6:211–23.
   PubMed Web of Science ®Google Scholar
• Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2008;26:4798–805.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–84.
   PubMed Web of Science ®Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467–72.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67:2982–9.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;115–30.
   PubMed Web of Science ®Google Scholar
• Jernberg H, Pettersson M, Kishimoto T, Nilsson K. Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines. Leukemia. 1991;5:255–65.
   PubMed Web of Science ®Google Scholar
• Spets H, Jernberg-Wiklund H, Sambade C, Soderberg O, Nilsson K. The effects on growth and survival of IL-6 can be dissociated in the U-266-1970/U-266-1984 and HL407E/HL407L human multiple myeloma cell lines. Br J Haematol. 1997;98:126–33.
   PubMed Web of Science ®Google Scholar
• Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 1996;88:2250–8.
   PubMed Web of Science ®Google Scholar
• Nilsson K, Jernberg H, Pettersson M. IL-6 as a growth factor for human multiple myeloma cells—a short overview. Curr Top Microbiol Immunol. 1990;166:3–12.
   PubMed Web of Science ®Google Scholar
• Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83–5.
   PubMed Web of Science ®Google Scholar
• Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6- responsive human myeloma cell line growth. J Immunol. 1997;159:487–96.
   PubMed Web of Science ®Google Scholar
• Jernberg-Wiklund H, Nilsson K. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I). Adv Cancer Res. 2007;97:139–65.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia. 2005;19:2177–85.
   PubMed Web of Science ®Google Scholar
• Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M, Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood. 2003;101:2775–83.
   PubMed Web of Science ®Google Scholar
• Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630–6.
   PubMed Web of Science ®Google Scholar
• Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood. 1999;93:235–41.
   PubMed Web of Science ®Google Scholar
• LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127–37.
   PubMed Web of Science ®Google Scholar
• Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res. 1999;5:1935–44.
   PubMed Web of Science ®Google Scholar
• Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem. 2002;277:39684–95.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5:221–30.
   PubMed Web of Science ®Google Scholar
• Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A, Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood. 2002;100:3925–9.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, Clinical implication of centrosome amplification in plasma cell neoplasm. Blood. 2006;107:3669–75.
   PubMed Web of Science ®Google Scholar
• Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA. 1993;90:11217–21.
   PubMed Web of Science ®Google Scholar
• Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2002;1:339–53.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther. 2005;5:487–99.
   PubMed Web of Science ®Google Scholar
• Nilsson K, Georgii-Hemming P, Spets H, Jernberg-Wiklund H. The control of proliferation, survival and apoptosis in human multiple myeloma cells in vitro. Curr Top Microbiol Immunol. 1999;246:325–32; discussion 33.
   PubMed Web of Science ®Google Scholar
• Georgii-Hemming P, Stromberg T, Janson ET, Stridsberg M, Wiklund HJ, Nilsson K. The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. Blood. 1999;93:1724–31.
   PubMed Web of Science ®Google Scholar
• Ogawa M, Nishiura T, Oritani K, Yoshida H, Yoshimura M, Okajima Y, Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res. 2000;60:4262–9.
   PubMed Web of Science ®Google Scholar
• Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res. 2010;70:6412–19.
   PubMed Web of Science ®Google Scholar
• Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat. 2006;95:211–18.
   PubMed Web of Science ®Google Scholar
• Deng H, Lin Y, Badin M, Vasilcanu D, Stromberg T, Jernberg-Wiklund H, Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9. Biochem Biophys Res Commun. 2011;404:667–71.
   PubMed Web of Science ®Google Scholar
• Vanderkerken K, Van Camp B, De Greef C, Vande Broek I, Asosingh K, Van Riet I. Homing of the myeloma cell clone. Acta Oncol. 2000;39:771–6.
   PubMed Web of Science ®Google Scholar
• Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J. 2000;1:351–6.
   PubMedGoogle Scholar
• Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196–206.
   PubMed Web of Science ®Google Scholar
• Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer. 2007;121:1857–61.
   PubMed Web of Science ®Google Scholar
• Hartog H, Wesseling J, Boezen HM, van der Graaf WT. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer. 2007;43:1895–904.
   PubMed Web of Science ®Google Scholar
• Buck E, Mulvihill M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig Drugs. 2011;20:605–21.
   PubMed Web of Science ®Google Scholar
• Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. 2006;107:669–78.
   PubMed Web of Science ®Google Scholar
• Menu E, Jernberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O, Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood. 2006;107:655–60.
   PubMed Web of Science ®Google Scholar
• Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004;64:236–42.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 2008;26:3196–203.
   PubMed Web of Science ®Google Scholar
• Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother. 2007;56:343–57.
   PubMed Web of Science ®Google Scholar
• Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials—early lessons. J Mammary Gland Biol Neoplasia. 2008;13:471–83.
   PubMed Web of Science ®Google Scholar
• Hashemi J, Worrall C, Vasilcanu D, Fryknas M, Sulaiman L, Karimi M, Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP). PLoS One. 2011;6:e14757.
   Web of Science ®Google Scholar
• Vasilcanu D, Weng WH, Girnita A, Lui WO, Vasilcanu R, Axelson M, The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene. 2006;25:3186–95.
   PubMed Web of Science ®Google Scholar
• Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA. 2010;107:10791–8.
   PubMed Web of Science ®Google Scholar
• Ekman S, Frodin JE, Harmenberg J, Bergman A, Hedlund A, Dahg P, Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011;5:441–7.
   Google Scholar
• Stromberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K, Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004;103:3138–47.
   PubMed Web of Science ®Google Scholar
• Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 2004;104:4181–7.
   PubMed Web of Science ®Google Scholar
• Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia. 2006;20:1254–60.
   PubMed Web of Science ®Google Scholar
• Maiso P, Ocio EM, Garayoa M, Montero JC, Hofmann F, Garcia-Echeverria C, The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol. 2008;141:470–82.
   PubMed Web of Science ®Google Scholar
• Lemaire M, Fristedt C, Agarwal P, Menu E, Valckenborgh E, De Bryune E, The HDAC inhibitor LBH589 enhances the anti-myeloma effect of the IGF-1 RTK inhibitor picropodophyllin. Submitted 2011.
   Google Scholar
• Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745–57.
   PubMed Web of Science ®Google Scholar
• Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692–700.
   PubMed Web of Science ®Google Scholar
• Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006;20:1123–36.
   PubMed Web of Science ®Google Scholar
• Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell. 2004;118:409–18.
   PubMed Web of Science ®Google Scholar
• Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40:499–507.
   PubMed Web of Science ®Google Scholar
• Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469:343–9.
   PubMed Web of Science ®Google Scholar
• Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846–56.
   PubMed Web of Science ®Google Scholar
• Richly H, Aloia L, Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis. 2011;2:e204.
   PubMed Web of Science ®Google Scholar
• Fisher CL, Fisher AG. Chromatin states in pluripotent, differentiated, and reprogrammed cells. Curr Opin Genet Dev. 2011;21:140–6.
   PubMed Web of Science ®Google Scholar
• Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 2007;67:10657–63.
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624–9.
   PubMed Web of Science ®Google Scholar
• Jagani Z, Wiederschain D, Loo A, He D, Mosher R, Fordjour P, The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer Res. 2010;70:5528–38.
   PubMed Web of Science ®Google Scholar
• Brenning G. The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol. 1985;35:178–85.
   PubMedGoogle Scholar
• Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68:190–7.
   PubMed Web of Science ®Google Scholar
• Van Valckenborgh E, Matsui W, Agarwal P, Lub S, Dehui X, De Bruyne E, Menu E, Empsen C, van Grunsven L, Agarwal J, Wang Q, Jernberg-Wiklund H, Vanderkerken K. Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model. Leukemia. 2012 Jan 6. doi: 10.1038/leu.2011.373. [Epub ahead of print].
   Google Scholar
• Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet. 2007;39:237–42.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40:741–50.
   PubMed Web of Science ®Google Scholar